菜单
>

Discovery

Related services:

 

  • Engineering of novel Fc variants
  • Optimized Fc domain with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), extended half-life and improved thermostability (WuXi Biologics patent pending)
  • Binding affinity test to Fc receptors, FcRn, C1q
  • ADCC/ADCP/CDC assays